Pierre‐François Laterre

Research interests

Publications

• SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule

  Kidney International · 2020 · https://doi.org/10.1016/j.kint.2020.07.019

• The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study

  Clinical Infectious Diseases · 2020 · https://doi.org/10.1093/cid/ciaa224

• Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock

  JAMA · 2019 · https://doi.org/10.1001/jama.2019.14607

• Determinants of long-term outcome in ICU survivors: results from the FROG-ICU study

  Critical Care · 2018 · https://doi.org/10.1186/s13054-017-1922-8

• Impact of Very Early Physical Therapy During Septic Shock on Skeletal Muscle: A Randomized Controlled Trial

  Critical Care Medicine · 2018 · https://doi.org/10.1097/ccm.0000000000003263

• Guidelines for management of intra-abdominal infections

  Anaesthesia Critical Care & Pain Medicine · 2015 · https://doi.org/10.1016/j.accpm.2015.03.005

• Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis

  JAMA · 2013 · https://doi.org/10.1001/jama.2013.2194

• Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock

  Critical Care · 2010 · https://doi.org/10.1186/cc8945

• Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock

  Critical Care · 2010 · https://doi.org/10.1186/cc9091

• Neurally adjusted ventilatory assist improves patient–ventilator interaction

  Intensive Care Medicine · 2010 · https://doi.org/10.1007/s00134-010-2052-9

• Toll-like Receptor 4 Modulation as a Strategy to Treat Sepsis

  Mediators of Inflammation · 2010 · https://doi.org/10.1155/2010/568396

• The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock

  Intensive Care Medicine · 2009 · https://doi.org/10.1007/s00134-009-1603-4

• Hydrocortisone Therapy for Patients with Septic Shock

  New England Journal of Medicine · 2008 · https://doi.org/10.1056/nejmoa071366

• Early Antibiotic Treatment for Severe Acute Necrotizing Pancreatitis

  Annals of Surgery · 2007 · https://doi.org/10.1097/01.sla.0000250414.09255.84

• Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death

  New England Journal of Medicine · 2005 · https://doi.org/10.1056/nejmoa050935

• Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study*

  Critical Care Medicine · 2005 · https://doi.org/10.1097/01.ccm.0000162381.24074.d7

• The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis *

  Critical Care Medicine · 2004 · https://doi.org/10.1097/01.ccm.0000145228.62451.f6

• Effect of Recombinant Surfactant Protein C–Based Surfactant on the Acute Respiratory Distress Syndrome

  New England Journal of Medicine · 2004 · https://doi.org/10.1056/nejmoa033181

• Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis*

  Critical Care Medicine · 2003 · https://doi.org/10.1097/00003246-200301000-00001

• Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

  Critical Care Medicine · 2003 · https://doi.org/10.1097/00003246-200301000-00002

• Drotrecogin Alfa (activated) Improves In-hospital and 90-day Survival in Patients With Severe Sepsis and Community-acquired Pneumoni

  CHEST Journal · 2003 · https://doi.org/10.1378/chest.124.5.1789

• Compartmentalization of the Inflammatory Response during Acute Pancreatitis

  American Journal of Respiratory and Critical Care Medicine · 2003 · https://doi.org/10.1164/rccm.2204019

• Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial

  Intensive Care Medicine · 2003 · https://doi.org/10.1007/s00134-003-1731-1

• The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis (vol 28, pg 48, 2000)

  Digital Access to Libraries · 2001 · https://doi.org/10.1097/00003246-200111000-00003

• Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis

  New England Journal of Medicine · 2001 · https://doi.org/10.1056/nejm200103083441001

Current projects

No projects listed.